Cerity Partners LLC Boosts Stock Position in Boston Scientific Corporation $BSX

Cerity Partners LLC raised its position in shares of Boston Scientific Corporation (NYSE:BSX) by 3.2% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,265,524 shares of the medical equipment provider’s stock after purchasing an additional 39,345 shares during the quarter. Cerity Partners LLC’s holdings in Boston Scientific were worth $120,668,000 at the end of the most recent reporting period.

Several other large investors have also added to or reduced their stakes in BSX. Norges Bank purchased a new stake in Boston Scientific during the 4th quarter valued at about $2,199,395,000. Egerton Capital UK LLP grew its stake in Boston Scientific by 223.7% during the 3rd quarter. Egerton Capital UK LLP now owns 5,312,504 shares of the medical equipment provider’s stock valued at $518,660,000 after purchasing an additional 3,671,548 shares during the last quarter. Alphinity Investment Management Pty Ltd purchased a new stake in shares of Boston Scientific in the fourth quarter worth about $252,918,000. Marshall Wace LLP boosted its stake in shares of Boston Scientific by 30.7% in the third quarter. Marshall Wace LLP now owns 9,799,040 shares of the medical equipment provider’s stock worth $956,680,000 after buying an additional 2,301,383 shares during the last quarter. Finally, Credit Agricole S A purchased a new stake in shares of Boston Scientific in the third quarter worth about $204,812,000. Hedge funds and other institutional investors own 89.07% of the company’s stock.

Insiders Place Their Bets

In other Boston Scientific news, Director Cheryl Pegus purchased 1,770 shares of the stock in a transaction on Wednesday, May 20th. The shares were bought at an average price of $56.49 per share, for a total transaction of $99,987.30. Following the completion of the transaction, the director owned 1,770 shares of the company’s stock, valued at $99,987.30. This trade represents a ? increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Also, Director David C. Habiger purchased 2,250 shares of the stock in a transaction on Wednesday, May 20th. The shares were acquired at an average price of $55.92 per share, for a total transaction of $125,820.00. Following the transaction, the director directly owned 13,878 shares of the company’s stock, valued at $776,057.76. This represents a 19.35% increase in their position. The SEC filing for this purchase provides additional information. Over the last 90 days, insiders have acquired 9,800 shares of company stock worth $554,012. 0.34% of the stock is owned by corporate insiders.

Analyst Ratings Changes

A number of analysts have recently commented on the company. Truist Financial lowered their target price on Boston Scientific from $85.00 to $64.00 and set a “buy” rating on the stock in a research note on Thursday, June 4th. Jefferies Financial Group lowered their target price on Boston Scientific from $110.00 to $100.00 and set a “buy” rating on the stock in a research note on Wednesday, April 22nd. Needham & Company LLC restated a “buy” rating and issued a $77.00 target price on shares of Boston Scientific in a research note on Monday, May 18th. Wells Fargo & Company restated an “equal weight” rating and issued a $55.00 target price (down from $75.00) on shares of Boston Scientific in a research note on Thursday, May 28th. Finally, Citigroup lowered their target price on Boston Scientific from $87.00 to $70.00 and set a “buy” rating on the stock in a research note on Thursday, May 28th. One investment analyst has rated the stock with a Strong Buy rating, twenty-two have given a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, Boston Scientific currently has a consensus rating of “Moderate Buy” and a consensus target price of $85.92.

Boston Scientific Stock Performance

Shares of BSX stock opened at $48.73 on Tuesday. The company has a market capitalization of $72.42 billion, a P/E ratio of 20.39, a P/E/G ratio of 0.91 and a beta of 0.56. The business’s 50 day moving average is $57.68 and its two-hundred day moving average is $76.17. The company has a current ratio of 1.90, a quick ratio of 1.22 and a debt-to-equity ratio of 0.42. Boston Scientific Corporation has a 12-month low of $47.17 and a 12-month high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, April 22nd. The medical equipment provider reported $0.80 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.79 by $0.01. The company had revenue of $5.20 billion for the quarter, compared to the consensus estimate of $5.19 billion. Boston Scientific had a return on equity of 19.17% and a net margin of 17.29%.Boston Scientific’s revenue for the quarter was up 11.6% on a year-over-year basis. During the same quarter in the prior year, the business posted $0.75 earnings per share. Boston Scientific has set its Q2 2026 guidance at 0.820-0.840 EPS and its FY 2026 guidance at 3.340-3.410 EPS. Analysts expect that Boston Scientific Corporation will post 3.37 EPS for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a share repurchase plan on Monday, May 18th that permits the company to buyback $5.00 billion in shares. This buyback authorization permits the medical equipment provider to buy up to 6.4% of its shares through open market purchases. Shares buyback plans are usually a sign that the company’s board of directors believes its shares are undervalued.

Boston Scientific Profile

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.